Sanofi (SNY) NASDAQ

48.12

-0.43(-0.89%)

Updated at July 15 04:00PM

Currency In USD

Sanofi

Address

54, Rue La BoEtie

Paris, 75008

France

Phone

33 1 53 77 40 00

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

82878

First IPO Date

July 01, 2002

Key Executives

NameTitlePayYear Born
Mr. Paul HudsonChief Executive Officer & Director4.45M1967
Ms. Madeleine RoachExecutive Vice President & Head of Business Operations01984
Mr. Roy PapatheodorouExecutive Vice President & General Counsel01978
Mr. Thomas Kudsk LarsenHead of Investor Relations01974
Mr. Olivier CharmeilExecutive Vice President of General Medicines01963
Ms. Marie-Hélène LaimaySenior Vice President of Audit & Internal Control Assessment01959
Dr. Frank NestleGlobal Head of Immunology & Inflammation Research and Chief scientific Officer - North America0N/A
Ms. Natalie BickfordExecutive Vice President & Chief People Officer01970
Mr. Pierre ChancelSenior Vice President of Global Diabetes and Senior Vice President of Global Marketing01957
Mr. François-Xavier RogerExecutive Vice President & Chief Financial Officer01962

Description

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.